BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31940975)

  • 1. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG.
    Nikolaev A; Fiveash JB; Yang ES
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
    Katagi H; Louis N; Unruh D; Sasaki T; He X; Zhang A; Ma Q; Piunti A; Shimazu Y; Lamano JB; Carcaboso AM; Tian X; Seluanov A; Gorbunova V; Laurie KL; Kondo A; Wadhwani NR; Lulla R; Goldman S; Venneti S; Becher OJ; Zou L; Shilatifard A; Hashizume R
    Clin Cancer Res; 2019 Sep; 25(18):5572-5583. PubMed ID: 31227500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
    Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
    Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
    Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential.
    Kfoury-Beaumont N; Prakasam R; Pondugula S; Lagas JS; Matkovich S; Gontarz P; Yang L; Yano H; Kim AH; Rubin JB; Kroll KL
    BMC Biol; 2022 May; 20(1):124. PubMed ID: 35637482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
    Chen H; Huang Y; Zhu X; Liu C; Yuan Y; Su H; Zhang C; Liu C; Xiong M; Qu Y; Yun P; Zheng L; Huang K
    J Physiol; 2019 Mar; 597(6):1643-1660. PubMed ID: 30516825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
    Lu VM; Daniels DJ
    Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
    Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
    Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
    Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():92. PubMed ID: 30873381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.